Holen Sie sich die Stockscreener-App
2.885
6.03%
-0.185
Schlusskurs vom Vortag:
$3.07
Offen:
$3.08
24-Stunden-Volumen:
192.13K
Relative Volume:
0.05
Marktkapitalisierung:
$9.13M
Einnahmen:
$129.20K
Nettoeinkommen (Verlust:
$-7.44M
KGV:
-0.2578
EPS:
-11.19
Netto-Cashflow:
$-8.62M
1W Leistung:
+8.87%
1M Leistung:
-44.20%
6M Leistung:
+84.94%
1J Leistung:
-51.27%
1-Tages-Spanne:
$2.80
$3.17
1-Wochen-Bereich:
$2.48
$3.5897
52-Wochen-Spanne:
$1.08
$19.30
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Firmenname
Sonnet Biotherapeutics Holdings Inc
Sektor
Branche
Telefon
609-375-2227
Adresse
100 OVERLOOK CENTER, PRINCETON, NJ
Vergleichen Sie SONN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
2.885 | 20.17M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.83 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.02 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.76 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.05 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.08 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc Aktie (SONN) Neueste Nachrichten
Why Sonnet BioTherapeutics Holdings Inc. stock attracts strong analyst attentionStrong MACD Crossover Alerts - thegnnews.com
Pilot Killed In NJ Crash Was CEO Of Cancer-Focused Biotech Company - MSN
Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewswire
Breakthrough: Sonnet's Ovarian Cancer Drug Achieves 67% Response Rate, Trial Expands with Higher Dose - Stock Titan
Why Did Sonnet BioTherapeutics Holdings Soar 11.49%? - AInvest
Sonnet Biotherapeutics Holdings Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here? - Barchart.com
Sonnet BioTherapeutics Expands Clinical Study of SON-1010 in Combination with Atezolizumab for Advanced Platinum-Resistant Ovarian Cancer - Quiver Quantitative
Sonnet BioTherapeutics Expands Clinical Evaluation of - GlobeNewswire
Cancer Drug Shows 66% Response Rate in Ovarian Cancer Trial: Sonnet BioTherapeutics Advances to Higher Dose - Stock Titan
Live Chart Scan Detects Wedge Pattern in Sonnet BioTherapeutics Holdings Inc.Swing Trade Entry With Volume Triggers Released - beatles.ru
Is Sonnet BioTherapeutics Holdings Inc. stock overvalued or undervaluedRecord-breaking capital gains - Jammu Links News
What is the dividend policy of Sonnet BioTherapeutics Holdings Inc. stockBuild wealth faster with disciplined trading - Jammu Links News
Why is Sonnet BioTherapeutics Holdings Inc. stock attracting strong analyst attentionCapitalize on proven investment strategies - Jammu Links News
How strong is Sonnet BioTherapeutics Holdings Inc. company’s balance sheetFree Daily Trading Room Entry - Jammu Links News
What analysts say about Sonnet BioTherapeutics Holdings Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
What are the latest earnings results for Sonnet BioTherapeutics Holdings Inc.Fastest return on investment - Jammu Links News
What institutional investors are buying Sonnet BioTherapeutics Holdings Inc. stockExpert guidance for superior capital growth - Jammu Links News
What is the risk reward ratio of investing in Sonnet BioTherapeutics Holdings Inc. stockTransform your portfolio with high-yield stocks - Jammu Links News
What drives Sonnet BioTherapeutics Holdings Inc. stock priceStay ahead with daily market updates - Jammu Links News
What catalysts could drive Sonnet BioTherapeutics Holdings Inc. stock higher in 2025Dynamic profit expansion - Jammu Links News
Is it the right time to buy Sonnet BioTherapeutics Holdings Inc. stockHigh-velocity gains - Jammu Links News
Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao - TipRanks
Sonnet BioTherapeutics enters employment agreement with interim CEO Raghu Rao - Investing.com Australia
Is this a good reentry point in Sonnet BioTherapeutics Holdings Inc.Earnings Play Trade Plan With Alerts Shared - metal.it
Is Sonnet BioTherapeutics Holdings Inc. a growth stock or a value stockBest Dividend Insights For Fast Growth - Jammu Links News
Real time social sentiment graph for Sonnet BioTherapeutics Holdings Inc.Daily Smart Money Movement Monitor Activated - metal.it
Published on: 2025-07-30 03:59:14 - metal.it
Published on: 2025-07-29 23:38:09 - metal.it
Published on: 2025-07-29 20:04:07 - metal.it
Pattern Scan Adds Sonnet BioTherapeutics Holdings Inc. to WatchlistWealth Building Stock Market Ideas Based on Momentum - beatles.ru
Analyzing net buyer seller activity in Sonnet BioTherapeutics Holdings Inc.Insider Strategy for High Conviction Picks - Newser
Sonnet BioTherapeutics Holdings Inc. Company Revenue and Profit Trends: A Deep DiveWeekly Double Return List - metal.it
How Interest Rate Changes Impact Sonnet BioTherapeutics Holdings Inc. Stock PerformanceFree Access to Community - Newser
Top Risks to Consider Before Buying Sonnet BioTherapeutics Holdings Inc. StockFree Deep Market Trend Analysis - Newser
Sonnet BioTherapeutics Regains Nasdaq Compliance After Fundraising - The Globe and Mail
Sonnet BioTherapeutics Holdings Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - PrintWeekIndia
Finanzdaten der Sonnet Biotherapeutics Holdings Inc-Aktie (SONN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
4.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):